Preclinical safety assessment considerations in vaccine development.
Bussiere
J L
JL
Department of Pathobiology and Toxicology, Genentech, Inc., South San Francisco, California 94080, USA.
McCormick
G C
GC
Green
J D
JD
D000818:Animals; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D014612:Vaccines / Q000009:adverse effects*; D014613:Vaccines, Attenuated / Q000009:adverse effects; D015164:Vaccines, Inactivated / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000009:adverse effects
D014612:Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic